Filing identity and reporting period
Important identity discrepancy: The request identifies Scienture Holdings, Inc., but the supplied Form 10-K is for Trxade Group, Inc. The filing covers the fiscal year ended December 31, 2015, not a standalone 2015 fourth quarter. The summary below reflects the filing text provided.
Trxade operated a business-to-business pharmaceutical marketplace and, through its Westminster subsidiary, distributed FDA-approved generic pharmaceuticals. Its marketplace connected independent pharmacies and pharmaceutical suppliers; the company reported more than 5,000 registered pharmacy members.
Financial results and liquidity
Amounts are in U.S. dollars. Fiscal 2015 results are compared with fiscal 2014.
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $4,992,203 | $1,496,227 |
| Cost of sales | $1,928,067 | $440,047 |
| Gross profit | $3,064,136 | $1,056,180 |
| Gross margin | 61.4% | 70.6% |
| Operating loss | $(987,047) | $(1,431,472) |
| Net loss | $(1,117,183) | $(2,012,043) |
| Basic and diluted loss per share | $(0.04) | $(0.07) |
| Cash used in operating activities | $(1,202,137) | $(1,064,576) |
| Cash provided by financing activities | $1,356,667 | $1,685,861 |
Revenue increased approximately 234% year over year, principally from marketplace fees and pharmaceutical distribution. Gross margin declined as distribution, which carries higher cost of sales, expanded. General and administrative expense was $3,696,067; stock-option and warrant expense was $355,116. Interest expense was $130,136, compared with $4,154 in 2014. The 2014 net loss included a $576,417 loss on debt conversion.
At December 31, 2015, cash was $860,132, total current assets were $2,027,670, current liabilities were $1,052,265, and reported working capital was $975,405. Total assets were $2,027,670; total liabilities were $1,760,653; and shareholders’ equity was $267,017. Debt was reported net of discounts: $235,000 in notes payable, $164,303 in short-term convertible notes, and $708,388 in long-term convertible notes. The filing describes $1.4 million in aggregate debt borrowings/obligations.
Westminster reported 2015 revenue of $2,079,678 and a segment loss of $1,341,046; Trxade reported revenue of $2,745,589 and segment profit of $292,438. Corporate overhead allocated to segments was $1,138,558.
Material changes and financing
- Revenue grew sharply, while the net loss narrowed; operating cash use increased by about $138,000.
- Inventory rose to $284,718 from $46,429, and accounts receivable rose to $498,100 from $349,025.
- The company raised $950,000 through three-year convertible notes in November and December 2015. The notes carry quarterly payments based on a percentage of profits from specified Westminster transactions and are convertible at $2.50 per share; accompanying warrants have a $0.01 exercise price.
- It also issued $200,000 of one-year convertible notes, bearing 10% interest and convertible at $1.50 per share, and a $250,000 face-value promissory note with $205,000 cash proceeds after original issue discount.
- Management said 2016 operating expenses and working-capital requirements were estimated at $7.7 million, including $5.3 million of cost of sales and $2.4 million of general and administrative expense. It expected to seek additional capital and stated there was no assurance financing would be available on acceptable terms.
Outlook, risks, and unusual items
- Management’s 2016 priorities were to develop the Trxade platform, expand the customer base, and increase operating revenue. It expected to expand Westminster private-label sales. The Pinnacle Tek consulting business was discontinued in early 2016.
- The company disclosed a limited operating history, recurring losses, ongoing cash needs, no traditional bank credit facility, and uncertainty about achieving profitability or positive operating cash flow. Management said sales needed to increase approximately two-fold to break even.
- Regulatory and operating risks include state restrictions on pharmacy-to-pharmacy trading, pharmaceutical track-and-trace requirements, supplier concentration, third-party logistics reliance, product quality/counterfeit and credit risks, and competition from substantially larger distributors.
- A putative class action filed in November 2015 alleges unlawful “junk fax” advertising and seeks statutory damages. Management denied material liability but stated damages or settlement costs were more likely than not; the amount could not be determined and no accrual was recorded.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing material weaknesses in accounting policies, financial close/reporting, systems, staffing, and segregation of duties. The external auditor issued an unmodified opinion on the financial statements but did not express an opinion on control effectiveness.
- The filing reports thin and sporadic OTC trading, penny-stock status, and concentrated ownership: the CEO and president together beneficially owned approximately 84.6% of shares. The CEO’s annual salary was increased from $100,000 to $165,000 in an amendment after year-end, disclosed in the filing.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Trxade Group, Inc., not Scienture Holdings, Inc., and confirm the intended reporting period.
- Review the audited financial statements and debt notes for exact principal, discounts, maturities, conversion terms, warrant counts, and the profit-based note payment provisions.
- Assess whether cash, working capital, and available financing can support the stated 2016 cost and operating plan; the filing gives no assurance that additional funding will be obtained.
- Track the fax-advertising class action, potential exposure, and any later accrual, settlement, or outcome.
- Monitor remediation of the disclosed material weaknesses and confirm subsequent filings provide evidence of improved controls.
- Reconcile segment results, corporate overhead allocation, and the mix and margins of marketplace versus Westminster distribution revenue as the business expands.